Preveen Ramamoorthy PhD

  • Director, Molecular Diagnostics Laboratory
  • Assistant Professor
Phone
303-398-1505
Email
ramamoorthyp@njhealth.org
Gender
Male

Research Interests

To develop and deploy rapid molecular diagnostic, molecular prognostic, pharmacogenomic companion diagnostic and molecular genetic tests. To catalyze and drive translation of existing/novel biomarkers into clinically useful molecular diagnostics tests . To innovate by developing/co-developing novel molecular diagnostics technologies. To partner with drug development, diagnostics and technology companies to enable the development of companion diagnostics and molecular diagnostics. To create molecular diagnostics training programs to enable physicians, scientists and students to participate in the era of molecular medicine.

Service

Education & Training

Education

Clemson University
PhD, Microbiology, 2000
University of Madras, India
MS, Medical Microbiology, 1995

Fellowships

Walter Reed Army Institute of Research (Silver Spring, MD)
2002

Awards & Recognition

Reviewer, Journal of Asthma

Albert Krall Memorial Award, 8th Annual South Carolina Statewide Research Conference: Molecular Approaches to Biological Problems, January 1999, Wild Dunes

Executive committee member of EPPIC, a life sciences entrepreneurial organization (http://www.eppicglobal.org), 2003-2007

Recent or Important Publications

Preveen Ramamoorthy, Rina Das, Niranjan Kanesa-Thasan, Robert Putnak and Marti Jett. Host Immune Gene Expression Profiling In the Diagnosis of DEN Infection and Application of Nanogen’s Microelectronic/Microfluidics Chip to Profile Host Immune Gene Expression Responses. 23rd Army Science Conference: “Transformational Science & Technology for the Army...a race for speed and precision.” Orlando, FL, 2-5 December 2002.

Marti Jett, Boris Ionin, Rina Das, Preveen Ramamoorthy and Roger Neill. Enterotoxins: Thomas E. Creighton (ed.) Encyclopedia of Molecular Medicine. New York: John Wiley & Sons, 2002, ISBN: 0-471-37494-6.

Ramamoorthy P, Wagner TE, Chen WY. In Vitro Effects of a Human Prolactin Antagonist, hPRL-G129R in Breast Cancer Cells. International Journal of Oncology, January 2001, 18 (1): 25-32.

Cataldo LA, Chen NY, Qiu Y, Li W, Ramamoorthy P, Wagner TE, Chen WY. Inhibition of the Oncogene STAT3 by a Human Prolactin (PRL) Antagonist is a PRL Receptor Specific Event. International Journal of Oncology, December 2000; 17 (6): 1179-85.

Chen WY, Ramamoorthy P, Chen NY, Sticca R, Wagner TE. A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis. Clinical Cancer Research, November 1999, 5:3583-3593.

Curriculum Vitae

View Curriculum Vitae

Appointments


1-800-222-5864

Congratulations to Our 28 "Top Docs"


Twenty-eight physicians at National Jewish Health were named "Top Docs" in the annual ranking by 5280 magazine.
Learn more
.

Personalized Medicine


National Jewish Health is at the forefront of a new era in healthcare - personalized medicine.

Our science is truly transforming the lives of millions. Learn more.

Media Center


In the Media Center, you can find National Jewish Health press releases, newsletters, annual reports and media contacts. Learn more.